U.S. High Intensity Focused Ultrasound Therapy Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: High Intensity Focused Ultrasound Therapy
- ✓Market Size 2024: USD 412 million
- ✓Market Size 2032: USD 1.08 billion
- ✓CAGR: 12.8%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Pre-Coverage Capital Planning: Hospital capital buyers should engage Medicare Administrative Contractors and CMS TCET applicants before the 2026 budget cycle closes. Secure documented CPT 55880 reimbursement pathways before committing to an Exablate or TULSA-PRO purchase, because unreimbursed installs erode margin within 18 months.
Focused Ultrasound Therapy in the U.S.: Market Overview
The U.S. high intensity focused ultrasound therapy market was valued at USD 412 million in 2024 and is projected to reach USD 1.08 billion by 2032. Its shape is set by Food and Drug Administration premarket approval under Section 515 of the Federal Food, Drug, and Cosmetic Act, which gates each therapeutic indication. Insightec's Exablate Neuro, approved for essential tremor and later Parkinson's disease tremor, anchors the neurology segment, while FDA-cleared prostate ablation systems form the urology base.
Private manufacturers have led commercialization, with Profound Medical's TULSA-PRO and SonaCare Medical's Sonablate competing for urology capital budgets across academic centers. Government has been the dominant force in funding the science, as National Institutes of Health grants and the BRAIN Initiative underwrote early clinical trials that preceded device approvals. The result is a market where public research funding created the evidence base and private firms converted it into installed systems.
Policy-Driven Growth in the U.S. Focused Ultrasound Market
Three policy mechanisms are converting clinical evidence into procedure volume. First, FDA premarket approval under Section 515 of the Federal Food, Drug, and Cosmetic Act grants legally marketable indications, and each new indication opens a separately reimbursable clinical population. Second, Medicare payment for CPT code 55880, which covers transrectal HIFU prostate ablation, is set through the CMS Hospital Outpatient Prospective Payment System, and that rate determines whether urology departments purchase systems.
Third, the CMS Transitional Coverage for Emerging Technologies pathway allows conditional Medicare coverage with evidence development for devices that meet breakthrough criteria, shortening the gap between FDA approval and national payment. Manufacturers holding FDA Breakthrough Device designation under Section 515B can enter TCET, which reduces the commercial lag that previously kept focused ultrasound systems in research settings for years after approval. This mechanism raises utilization of essential tremor and Parkinson's tremor procedures among Medicare-age patients.
Regulatory Barriers and Compliance Costs
Premarket review is the first barrier. The FDA's Center for Devices and Radiological Health reviews original PMA submissions under MDUFA V performance goals, with a target of 180 FDA review days for 90 percent of decisions. Clinical trial design requires investigational device exemption approval under 21 CFR Part 812 and institutional review board oversight under 21 CFR Part 56, typically adding 12 to 24 months before PMA submission.
State certificate-of-need laws create the second barrier. New York's Public Health Law Article 28 requires New York State Department of Health approval before hospitals acquire high-cost imaging-guided systems, and comparable regimes in Massachusetts and North Carolina add state review delays. The third barrier is quality compliance: the Quality Management System Regulation, amending 21 CFR Part 820 to align with ISO 13485:2016, takes effect February 2, 2026, requiring manufacturers to revalidate design controls.
Policy-Created Opportunities in U.S. Focused Ultrasound
Veterans Health Administration procurement offers a concrete opening. The VA's National Acquisition Center issues national contracts for medical devices, and VA medical centers treating tremor and Parkinson's patients form a volume buyer that can absorb systems without awaiting a Medicare coverage decision. Manufacturers securing national contract listings gain a federal reference customer that shortens hospital procurement cycles across the wider network.
NIH and BRAIN Initiative funding creates a second opportunity in neuromodulation. Focused ultrasound research is testing non-invasive modulation for depression, epilepsy, and Alzheimer's disease, and trials that obtain Breakthrough Device designation can enter TCET, which accelerates Medicare coverage for the resulting indication. Developers with early neuromodulation pipelines can target this pathway ahead of competitors lacking clinical data.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 412 million |
| Market Size 2032 | USD 1.08 billion |
| Growth Rate (CAGR) | 12.8% |
| Most Critical Decision Factor | Reimbursement coverage and FDA indication scope |
| Largest Region | Northeast census region |
| Competitive Structure | Concentrated, with few vendors holding most installed systems |
Leading Market Participants
- Insightec
- Profound Medical
- SonaCare Medical
- EDAP TMS
- Focus Surgery
- GE HealthCare
- Siemens Healthineers
- Philips
- Canon Medical Systems
- Theraclion
Regulatory and Policy Environment
The primary device legislation is the Federal Food, Drug, and Cosmetic Act of 1938 as amended by the Medical Device Amendments of 1976, which created premarket approval under Section 515 and classification under Section 510(k). The Food and Drug Administration administers it through the Center for Devices and Radiological Health. Key compliance requirements include PMA supplements for new indications, post-approval study obligations under 21 CFR Part 814, Medical Device Reporting under 21 CFR Part 803, and Unique Device Identification under 21 CFR Part 830.
Upcoming changes include the QMSR taking effect February 2, 2026, and MDUFA V expiring September 30, 2027, so MDUFA VI reauthorization must precede that date. Compared with the EU Medical Device Regulation (EU) 2017/745, the U.S. PMA route demands randomized evidence for novel therapies but delivers faster reimbursement pathways. Japan's PMDA requires local clinical data, while China's NMPA has approved domestic HIFU systems through a faster domestic pathway.
Long-Term Policy Outlook for Focused Ultrasound in the U.S.
By 2032, MDUFA VI will set FDA review goals for the next five-year period, and those performance commitments will determine whether focused ultrasound neuromodulation indications reach market within current timelines. CMS is expected to extend conditional coverage to additional indications as the TCET pathway accumulates completed coverage decisions. Each decision will expand the reimbursable population for Parkinson's tremor and neuromodulation.
Medicare site-neutral payment policy under annual OPPS rulemaking will likely move HIFU procedures from inpatient to ambulatory settings, lowering per-case costs and expanding procedure volume in ambulatory surgical centers. Hospitals that have invested in inpatient capacity will face margin pressure, while outpatient operators that secure early Medicare rate clarity will capture the expanded volume. Policy timing will therefore determine which care settings lead adoption through 2032.
Frequently Asked Questions
Market Segmentation
- Essential Tremor
- Parkinson's Disease Tremor
- Prostate Cancer Ablation
- Uterine Fibroid Ablation
- Neuromodulation Research
- Academic Medical Centers
- Community Hospitals
- Ambulatory Surgical Centers
- Veterans Affairs Medical Centers
- MR-Guided Focused Ultrasound
- Ultrasound-Guided HIFU
- Transrectal HIFU Systems
- Transcranial Focused Ultrasound
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.